Recombinant activated factor VII use in the emergency department

Emergency Medicine Journal

Volumn 25, Issue 10, 2008, Pages 625-630

  Fishman, P E ^a   Drumheller, B C ^a   Dubon, M E ^a   Slesinger, T L ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FRESH FROZEN PLASMA; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; EMERGENCY CARE; EMERGENCY MEDICINE; EMERGENCY WARD; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; OPTIMAL DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PHYSICIAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

COAGULANTS; EMERGENCY SERVICE, HOSPITAL; FACTOR VIIA; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS;

EID: 55349108198     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emj.2007.057158     Document Type: Review

References (39)

1. MacLaren R. Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion 2005; 45:1434-42.
2. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004;41(1 Suppl 1):101-8.
3. Stein DM, Dutton RP. Uses of recombinant factor VIIa it trauma. Curr Opin Crit Care 2004;10:520-8.
4. Jefferson R. New drug could help limit ICH injury. ACEP News September 2005;15-17.
5. Hedner U, Erhardsten E. Potential role of recombinant activated factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1:112-9.
6. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis. Anesthesiology 2004;100:722-30.
7. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005;33:883-90.
8. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998;4:790-8.
9. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997;78:1463-7.
10. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995;38:185-93.
11. Martinowitz R, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-9.
12. Boffard KD, Riou B. Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-18.
13. Stein DM, Dutton RP, O'Connor J, et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma 2005;59:609-15.
14. Rizoli SB, Boffard KD, Riou B, et al. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care 2006;10:R178.
15. Martinowitz U, Michaelson M. The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3:640-8.
16. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
17. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28:1-5.
18. Mayer SA, Brun NC, Begtrup K, et al (FAST Trial Investigators). Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127-37.
19. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology. prediction, and prevention. Am J Med 1993; 95:315-28.
20. Burt CW, McCaig LF. Trends in hospital emergency department utilization: United States, 1992-99. Vital Health Stat 2001; 13:1-34.
21. Newman DH, Zhitomirsky I. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med 2006; 48:182-9.
22. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004;181:492-7.
23. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-80.
24. Berntorp E. Recombinant FVIIa in the treatment of warfarin bleeding. Sem Thromb Haemost 2000;26:433-5.
25. Erhardtsen E, Nony P, Dechavanne, et al. The effect of recombinant factor VIIa (Novoseven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998;9:741-8.
26. Brody DL, Aiyagari V, Shackleford AM, et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005;2:263-7.
27. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004;79:1495-500.
28. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127:1123-30.
29. Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opinion Hematol 2001;8:312-8.
30. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352.
31. Poon MC, D'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004;2:1096-103.
32. Seremetis S. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul Fibrinolysis 2003;14(Suppl 1):S29-30.
33. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104:22-6.
34. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57:709-18.
35. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-5.
36. Martinowitz U, Kenet G, Lubetski A, et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002; 49:S15-20.
37. Clark AD, Gordon WC, Walker ID, et al. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004;86:120-4.
38. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
39. Earnshaw SR, Joshi AV, Wilson MR, et al. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006;37:2751-8.